<< Back to Results
ECOG E2905 - Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid(r)) Alone and in Combination with Epoeitn Alfa (Procrit(r)) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia.
Clinical Trial Categories
- The Rosenfeld Cancer Center at 215-481-2402
- The Rosenfeld Cancer Center